

HanchorBio teams up with National Taiwan University for advancement of precision oncology

August 10, 2026 | News

To accelerate biomarker-driven drug development and strengthen next-generation precision immunotherapy



HanchorBio, Inc., a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, has announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Programme (TCMP). The collaboration has been formalised through a Memorandum of Understanding signed by HanchorBio Taiwan and Professor Yu's team.

This strategic collaboration represents an important step in HanchorBio's evolution from a clinical-stage immunotherapy company toward a precision immunotherapy platform integrating patient-derived biological insights, biomarker strategies, proprietary therapeutic engineering, and global clinical development capabilities.

By combining TCMP's internationally recognised cancer multi-omics and translational research capabilities with HanchorBio's FBDB™ (Fc-Based Designer Biologics) platform and clinical-stage pipeline, the parties aim to accelerate the development of biomarker-driven immunotherapies and improve the precision of clinical development strategies.

Through this collaboration, HanchorBio and Professor Yu's team will explore how integrated molecular and immune profiling can support next-generation immunotherapy development, including:

- Identification of potential biomarkers associated with treatment response, resistance, and patient selection;
- Understanding how tumor biology influences innate and adaptive immune responses;
- Evaluating the relationship between macrophage-mediated immune regulation, T-cell functional states, and therapeutic outcomes;
- Integrating patient-derived molecular insights with clinical development strategies for HanchorBio's pipeline.